Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Cerebellum. 2018 Feb;17(1):72–77. doi: 10.1007/s12311-018-0917-6

Figure 2. Scheme for the development of AAV9-α1ACTQ33 hyperacute model of SCA6 in mice and the subsequent treatment with miRNA-3191.

Figure 2

A) Wildtype control C57BL/6J were intraventricular injected at P0 with recombinant AAV9 (adeno-associated virus) which expressed either α1ACTQ11 or α1ACTQ33 (AAV9- α1ACTQ11/Q33) under the control of the CACNA1A IRES.

B) Wildtype control C57BL/6J were intraventricular injected at P0 with both recombinant AAV9 (adeno-associated virus), which expressed α1ACTQ33 (AAV9- α1ACTQ33) under the control of the CACNA1A IRES and recombinant AAV9 that expressed miR-3191-5p.